Last reviewed · How we verify
NCT05605067: ARFID-GEN
Genetic Architecture of Avoidant/Restrictive Food Intake Disorder
trial in ARFID in 5,076 participants. Completed in 1 August 2024.
1 August 2024
Quick facts
| Lead sponsor | University of North Carolina, Chapel Hill |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,076 |
| Start date | 5 January 2023 |
| Primary completion | 1 August 2024 |
| Estimated completion | 1 August 2024 |
| Sites | 1 location across United States |
Conditions studied
- ARFID — all drugs for ARFID →
- Eating Disorders — all drugs for Eating Disorders →
- Eating Disorders in Children — all drugs for Eating Disorders in Children →
- Eating, Picky — all drugs for Eating, Picky →
Sponsor
University of North Carolina, Chapel Hill
Who can join
Adults 7 to 99, any sex, with ARFID or Eating Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to rapidly accelerate knowledge about the biology of avoidant and restrictive food intake disorder or ARFID in children ages 7-17 and in adults. The investigators will be evaluating the genetic and environmental origins of ARFID. Participants will be asked to answer questionnaires online and to submit a saliva sample for DNA using a kit that will be mailed to their home.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05605067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ARFID
Currently open trials in the same condition.
- NCT07431671 — Feeding Disorders in Children · NA · recruiting
- NCT07478510 — Cognitive Evaluation of Patients With Eating Disorders · recruiting
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
Other University of North Carolina, Chapel Hill trials
Trials by the same sponsor.
- NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
- NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
- NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
- NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
- NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05605067 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
- Last refreshed: 29 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05605067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing